Feb 13, 2017 13:01 pm UTC| Business
In one study most animals receiving the combination of CA4P and anti-CTLA4 antibody were tumor free at completionThree additional studies provide evidence that CA4P may enhance anti-CTLA4, anti-PD1, and anti-PD-L1 antibody...
Feb 13, 2017 13:01 pm UTC| Business
In one study most animals receiving the combination of CA4P and anti-CTLA4 antibody were tumor free at completionThree additional studies provide evidence that CA4P may enhance anti-CTLA4, anti-PD1, and anti-PD-L1 antibody...
Highway Holdings Reports Fiscal 2017 Third Quarter and Nine-Month Results
Feb 13, 2017 13:01 pm UTC| Business
HONG KONG, Feb. 13, 2017 -- Highway Holdings Limited (Nasdaq:HIHO) today reported results for its fiscal third quarter and nine months ended December 31, 2016. Net sales for the fiscal 2017 third quarter were $5.4...
Highway Holdings Reports Fiscal 2017 Third Quarter and Nine-Month Results
Feb 13, 2017 13:01 pm UTC| Business
HONG KONG, Feb. 13, 2017 -- Highway Holdings Limited (Nasdaq:HIHO) today reported results for its fiscal third quarter and nine months ended December 31, 2016. Net sales for the fiscal 2017 third quarter were $5.4...
VESTA Modular Acquires Assets of MSpace Holdings, LLC
Feb 13, 2017 13:01 pm UTC| Business
BIRMINGHAM, Mich., Feb. 13, 2017 -- VESTA Modular today announced that it received court approval to acquire substantially all assets of MSpace Holdings, LLC. The acquisition involves approximately 1,700 modular units...
VESTA Modular Acquires Assets of MSpace Holdings, LLC
Feb 13, 2017 13:01 pm UTC| Business
BIRMINGHAM, Mich., Feb. 13, 2017 -- VESTA Modular today announced that it received court approval to acquire substantially all assets of MSpace Holdings, LLC. The acquisition involves approximately 1,700 modular units...
AnaptysBio to Present Data from ANB020 Program at Two Upcoming Medical Meetings
Feb 13, 2017 13:01 pm UTC| Business
SAN DIEGO, Feb. 13, 2017 -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced...